Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TargetRx of Shenzhen Raises $21 Million for Novel Small Molecule Cancer Drugs

publication date: May 4, 2020

TargetRx, a Shenzhen company developing small molecules therapeutics for cancer, completed a $21.2 million Series A financing, led by CCB Principal Capital Management. Founded in 2014, the company is developing novel third/fourth generation candidates with the goal of avoiding acquired drug resistance. Proceeds from the funding will be used for clinical studies of the company’s chronic myeloid leukemia and non-small cell lung cancer treatments and other R&D. The founder of TargetRx, Dr. Yihan Wang, has previously discovered several first-in-class novel drugs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital